Reasons for attending the AAD meeting | AAD 2024
John Barbieri, assistant professor at Harvard Medical School, is looking forward to the upcoming 2024 American Academy of Dermatology meeting, which runs from March 8-12 in San Diego. Barbieri is particularly showing interest in late-breaking abstracts and trial data and hoping to see cutting-edge information from pivotal clinical trials.
John Barbieri, M.D., MBA, is one of the more 17,000 dermatologists and others attending the American Academy of Dermatology’s annual meeting this weekend in San Diego.
Barbieri, an assistant professor at Harvard Medical School, says he is looking forward to the fresh troves of data and the connecting with colleagues.
“I love seeing the new trial data as it comes out, and the late breaking research sessions are a good place to find those,” Barbieri said in a recent interview. “I also find that AAD is a great time to connect with colleagues. I think that's one of the best parts of this meeting is being able to see all of our colleagues in dermatology to think about how we can collaborate, to think about how we can move the field forward together.”
Barbieri specializes in inflammatory skin disease such as acne, rosacea, psoriasis and atopic dermatitis. He is the director of the Advanced Acne Therapeutics Clinic at the Harvard-affiliated Brigham and Women’s Hospital in Boston and is the co-chair of the academy’s acne guidelines work group.
He is speaking at four sessions at the meeting, which started today and ends on Tuesday. The sessions he is speaking are titled Great Care for Common Conditions: Combining Evidence and Cost Effectiveness; JAAD [Journal of the American Academy of Dermatology] game changers; Controversies in Acne and Rosacea; and Translating Evidence Into Practice: Acne Guidelines and Beyond.
Roflumilast Foam Showed Strong Results for Scalp and Body Psoriasis in Teens and Adults
May 7th 2025A new JAMA Dermatology study found that once-daily Zoryve (roflumilast) foam, 0.3%, safely and effectively reduced scalp and body plaque psoriasis symptoms in patients 12 and older, offering a convenient, and more tolerated treatment option that may boost adherence and quality of life.
Read More
Patients With Atopic Dermatitis Turn to Social Media but Trust Medical Advice Most
May 5th 2025A study found that while patients with atopic dermatitis often turn to social media for skincare advice, their decisions are most influenced by healthcare professionals, personal experience, and disease severity.
Read More
Most Patients With HS Aren’t Aware of Approved Treatments
May 1st 2025Treating hidradenitis suppurativa is complex and often requires taking a number of medications, including antibiotics, hormone therapies and immunosuppressants. However, many of these treatments are used off-label, and at this time, only two biologic therapies—Humira (adalimumab) and Cosentyx (secukinumab)— are approved by the FDA for HS treatment.
Read More
